Clinical trials: Ovarian Cancers
PCOS
IVM Versus Standard IVF in Infertile Patients Diagnosed With PCOS
A single center, prospective, open-label, non-inferiority randomized controlled clinical trials (1:1 treatment ratio) regarding pregnancy outcomes between IVM and standard IVF among infertility couples with PCOS in China.
- Trial name
- NCT03463772
- Testing
- standard IVF, In vitro maturation
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Jie Qiao
Ovarian Cancer
Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer
This prospective, multicenter, open-label, randomized phase II maintenance study is evaluating the efficacy of UV1-olaparib-durvalumab combination as maintenance therapy after platinum combination therapy for BRCAwt patients with…
- Trial name
- DOVACC (NCT04742075)
- Testing
- Olaparib + durvalumab + UV1
- Where
- Denmark
- Volunteers
- 188 people
- Sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Polycystic Ovary Syndrome, Infertility
Therapy for Infertile PCOS Patients Ovulating Under Clomiphene Citrate or Metformin
Several data demonstrated that both clomiphene citrate (CC) and metformin are two safe and valid first-step options to induce ovulation in infertile anovulatory PCOS patients.
- Trial name
- NCT00502229
- Testing
- Clomiphene citrate, metformin, highly purified urinary FSH
- Where
- Italy
- Sponsor
- University Magna Graecia
Ovarian Cancer, Primary PERITONEUM
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
The purpose of this study is to test whether it is safe to treat your cancer with 3 drugs instead of 2 drugs. After surgery, your cancer is typically treated with 2 drugs called cisplatin and paclitaxel (also known as Taxol).
- Conditions
- Ovarian Cancer, Primary PERITONEUM, Fallopian Tube Cancer
- Trial name
- NCT00588237
- Testing
- Paclitaxel,Cisplatin, Bevacizumab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumor
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile of M9466 with and without tuvusertib or an ARPi and early signs of clinical activity of M9466 with tuvusertib in…
- Trial name
- NCT06421935
- Testing
- M9466, Tuvusertib, Abiraterone acetate
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 60 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Granulosa Cell Tumour of the Ovary
Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary
Our proposal is to conduct an open phase II clinical trial that allows us to explore the activity of ketoconazole, an inhibitor of the enzyme CYP17, in ovarian granulosa tumors similar to what has been done in prostate cancer.
- Trial name
- GreKo (NCT01584297)
- Testing
- Ketoconazole
- Where
- 10 sites in Spain
- Volunteers
- 6 people
- Sponsor
- Grupo Español de Tumores Huérfanos e Infrecuentes
Polycystic Ovary
Serum Ghrelin in Polycystic Ovary Syndrome
measuring serum gherlin in polycystic ovary syndrome patients and compare it to healthy levels
- Trial name
- NCT02087410
- Where
- Egypt
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- amr hesham el etreby
Ovarian Cancer, Fallopian Tube Cancer
Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer
While significant progress has been made in the treatment and prognosis of ovarian cancer, this progress has mostly shown benefits for younger women.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Ovarian Diseases
- Trial name
- NCT02973750
- Testing
- Baseline Biopsy, Tissue Collection, Blood Draws
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced Solid Tumors, Solid Tumors
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
This will be a Phase 1, open label, 2-sequence, crossover study to establish the BE of the current commercial formulation (Generation 3.1 talazoparib capsules) to the proposed talazoparib liquid-filled soft gelatin capsule (soft…
- Conditions
- Advanced Solid Tumors, Solid Tumors, Ovarian Cancer, Breast Cancer
- Trial name
- NCT04672460
- Testing
- TALZENNA capsule, Talazoparib soft gel capsule
- Where
- 31 sites in United States, Australia
- Volunteers
- 73 people
- Sponsor
- Pfizer
Polycystic Ovary Syndrome, in Vitro Fertilization
Vitamin D and Pregnancy Outcome in PCOS Patients
This multicenter double-blinded placebo-controlled randomised trial aims to evaluate the effectiveness of vitamin D supplementation prior to IVF on the live birth rate in women with PCOS.
- Trial name
- NCT04082650
- Testing
- vitamin D
- Where
- 2 sites in China
- Volunteers
- 876 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Polycystic Ovarian Syndrome
Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome
This study examines Raloxifene versus Clomiphene to induce ovulation in women with polycystic ovarian syndrome (PCOS).
- Trial name
- PCOS (NCT01607320)
- Testing
- Raloxifene, Clomiphene
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Bruce Lessey
Polycystic Ovary Syndrome
The Effect of Dihydroartemisinin in PCOS
Artemisinin has been widely used as a first-line antimalarial drug in routine clinical practice. In recent years, it has been reported that Artemisinin also has some significant anti-inflammatory, anti-tumor and immune-modulating…
- Trial name
- NCT05465135
- Testing
- Dihydroartemisinin
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shanghai Zhongshan Hospital
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with…
- Conditions
- Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma
- Trial name
- FLORA-5 (NCT04498117)
- Testing
- Oregovomab, Paclitaxel, Carboplatin
- Where
- 148 sites in United States, Argentina and 12 more
- Volunteers
- 615 people
- Sponsor
- CanariaBio Inc.
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Ovarian Cancer
Study of XL999 in Patients With Previously Treated Ovarian Cancer
This clinical trial is being conducted at multiple sites to evaluate the activity, safety, and tolerability of XL999 when given weekly to patients with ovarian cancer that has previously been treated with platinum-based…
- Trial name
- NCT00277290
- Testing
- XL999
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Symphony Evolution, Inc.
Polycystic Ovary Syndrome
Effect of Weight & Insulin Sensitivity on Reproductive Function in PCOS: Studies in Skeletal Muscle & Adipose
The overall objective of this ancillary study is to obtain skeletal muscle and subcutaneous adipose tissue biopsies from women with polycystic ovary syndrome enrolled in the PULSE Study (NCT01482286).
- Trial name
- PULSE-A (NCT01775176)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Pennington Biomedical Research Center
Ovarian Cancer
Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer
Poly(ADP-ribose) polymerase (PARP) inhibitors are anti-cancer treatments that induce preferential tumor cell death. Their efficacy has been demonstrated in many tumor models, primarily in advanced ovarian cancer.
- Trial name
- PARIB-OLD-PRO² (NCT06572735)
- Testing
- QoL surveys, Geriatric assessment (G-CODE), Blood sampling
- Where
- 16 sites in France
- Volunteers
- 50 people
- Sponsor
- Hospices Civils de Lyon
Advanced Ovarian Cancer
SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS
The treatment of choice in advanced ovarian cancer is a cytoreductive surgery combined with chemotherapeutic treatment. This complex and aggressive surgery is associated with high postoperative complication rates that may result…
- Trial name
- SOPHIE (NCT04862325)
- Testing
- Multimodal Prehabilitation
- Where
- 2 sites in Spain
- Volunteers
- 158 people
- Sponsor
- Hospital Clinic of Barcelona
Ovarian Cancer, Fallopian Tube Cancer
Panitumumab and Gemcitabine in Relapsed Ovarian Cancer
This is a study to find out if the study drug, panitumumab, when given with gemcitabine works in treating ovarian cancer and to find out what side effects occur when they are given together.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- PanGem (NCT01296035)
- Testing
- Panitumumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Women and Infants Hospital of Rhode Island
Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum will…
- Conditions
- Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
- Trial name
- NCT01849874
- Testing
- MEK162, MEK inhibitor; oral, Physician's choice chemotherapy
- Where
- 226 sites in United States, Australia and 17 more
- Volunteers
- 341 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.